This site is intended for UK healthcare professionals
Medscape UK Univadis Logo
Medscape UK Univadis Logo

Olodaterol inhalation solution

Updated 2 Feb 2023 | Long acting beta agonists


Inhalation solution containing olodaterol (as hydrochloride).

Drugs List

  • olodaterol 2.5microgram inhalation solution cartridge with device
  • olodaterol 2.5microgram inhalation solution refill cartridge
  • STRIVERDI RESPIMAT 2.5microgram inhalation solution cartridge with device
  • STRIVERDI RESPIMAT 2.5microgram inhalation solution refill cartridge
  • Therapeutic Indications


    Chronic obstructive pulmonary disease



    Two inhalations once daily, at the same time of the day. The recommended dose should not be exceeded.


    Children under 18 years
    Long QT syndrome
    Torsade de pointes

    Precautions and Warnings

    Family history of long QT syndrome
    Predisposition to hypokalaemia
    Aortic aneurysm
    Cardiac arrhythmias
    Cardiovascular disorder
    Diabetes mellitus
    Electrolyte imbalance
    History of cardiac failure
    History of myocardial infarction
    History of torsade de pointes
    Hypertrophic obstructive cardiomyopathy
    Ischaemic heart disease
    Severe hepatic impairment
    Severe renal impairment
    Supraventricular tachycardia

    Anaesthetist should be made aware patient is taking this medication
    Correct electrolyte disorders before treatment
    Advise ability to drive/operate machinery may be affected by side effects
    Ensure patient has a fast acting bronchodilator available
    Contains benzalkonium chloride: may cause wheezing & breathing difficulties
    Check patient is using correct inhaler technique
    Monitor blood glucose closely in patients with diabetes mellitus
    Monitor closely patient at risk of cardiovascular disorders
    Monitor ECG in patients at risk of QT prolongation
    Monitor serum electrolytes
    Monitor serum K+ in patients on high dose steroids/xanthines/diuretics
    Advise patient to report new or worsening signs of cardiac failure
    May reduce serum potassium levels
    Discontinue if paradoxical bronchospasm occurs
    Advise patient not to use for relief of acute attacks
    Advise patient to seek medical advice if treatment is ineffective
    Use regularly to maintain freedom from symptoms

    Caution needs to be taken in case of a planned operation with halogenated hydrocarbon anaesthetics due to an increased susceptibility to the adverse cardiac effects of beta agonist bronchodilators.

    Pregnancy and Lactation


    Use olodaterol with caution during pregnancy.

    The manufacturer advises that it is preferable to avoid the use of olodaterol in pregnancy. Animal studies do not indicate direct or indirect harmful effects regarding reproductive toxicity at clinically relevant exposures. There is little data on the use of olodaterol in pregnant women. Risks are unknown.

    Olodaterol may inhibit labour as beta2-adrenergic agonists have a relaxant effect on uterine smooth muscle.


    Olodaterol is contraindicated during breastfeeding.

    The manufacturer advises discontinuing breastfeeding or discontinuing olodaterol. It is unknown whether olodaterol or its metabolites are excreted in human milk. In animal studies excretion of olodaterol and its metabolites have been detected in milk. It is not known whether either of the substances pass into human breast milk. Since there is negligible systemic exposure of the breastfeeding woman to olodaterol and/or its metabolites at a human dose of 5microgram per day, effects on the breastfed newborn/infant are not expected.

    Side Effects

    Angina pectoris
    Dry mouth
    Hypersensitivity reactions
    Metabolic acidosis
    Muscle spasm
    Myocardial ischaemia


    It is strongly recommended that the UK National Poisons Information Service be consulted on cases of suspected or actual overdose where there is doubt over the degree of risk or about appropriate management.

    The following number will direct the caller to the relevant local centre (0844) 892 0111

    Information may be obtained if you have access to ToxBase the primary clinical toxicology database of the National Poisons Information Service. This is available via password on the internet ( ) or if this is unavailable at the backup site ( ).

    Further Information

    Last Full Review Date: March 2021

    Reference Sources

    Summary of Product Characteristics: Striverdi Respimat 2.5 microgram, solution for inhalation. Boehringer Ingelheim International GmbH. Revised December 2020.

    Access the full UK drug database with a FREE Medscape UK Account
    It takes just a few minutes, and you’ll get unlimited access to information on over 11,000 UK drugs.
    Register for Free

    Already a member? Log in

    Medscape UK | Univadis prescription drug monographs & interactions are based on FDB Multilex Content

    FDB Logo

    FDB Disclaimer : FDB Multilex is intended for the use of healthcare professionals and is provided on the basis that the healthcare professionals will retain FULL and SOLE responsibility for deciding what treatment to prescribe or dispense for any particular patient or circumstance.